| Value | ₹1,170 Cr |
|---|
BSE filing, NSE: EMBDL. Summary written from the filing by ALFA Finder's alert engine.
Embassy Developments Ltd: key numbers
- Share price
- ₹49.48
- Market cap
- ₹6,996 Cr
- Revenue (annual)
- ₹1,732 Cr
- Net profit (annual)
- ₹-872.6 Cr
- P/E (TTM)
- -7.4×Sector 34.4×
- Promoter holding
- 42.68%+0.03% QoQ
- FII holding
- 24.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Embassy Developments Ltd
All →Embassy Developments Convertible Warrants
Embassy Developments allotted 93,18,900 equity shares to promoter group entity Embassy Property Developments on conversion of warrants. The company received the balance consideration of about Rs.77.94 Crore, completing the warrant conversion.
- Value
- ₹77.94 Cr
Embassy Developments Acquisition Worth ₹32.65 Cr
Embassy Developments signed an SPA to acquire 50% of Embassy Columbia Pacific ASL for ₹32.65 Crore. The JV will become wholly owned upon closing by December 2026.
- Value
- ₹32.65 Cr
- Execution
- Within the current quarter ending on December 31, 2026
Embassy Developments Convertible Warrants
Embassy Developments' promoter group entity converted 2.32 crore warrants into equity at INR 111.51 each. The conversion is valued at INR 258.70 crore.
- Value
- ₹258.7 Cr
Embassy Developments Board Meeting Date
Embassy Developments intimated a board meeting on 03 Nov 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The trading window stays closed until 05 Nov 2026.
Embassy Developments Convertible Warrants
Embassy Developments allotted 1,22,00,000 equity shares on conversion of preferential warrants. Paid-up capital rises by Rs 2.44 Crore to Rs 282.77 Crore.
- Value
- ₹2.44 Cr
Embassy Developments Convertible Warrants
Embassy Developments allotted 1,22,00,000 equity shares on conversion of promoter-group warrants, receiving Rs.102.03 Crore balance consideration. The conversion lifts promoter group holding to 43.62%.
- Value
- ₹102.0 Cr
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr